Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 12/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516649 | 0.90 | KMT2A (0.62) | KMT2AMEN1PKMGAAMAPT | |
| SCHEMBL108993 | 0.90 | KMT2A (0.62) | KMT2AMEN1PKMGAAMAPT | |
| SCHEMBL5697243 | 0.86 | KMT2A (0.60) | KMT2AMEN1PKMGAAMAPT | |
| SCHEMBL117698 | 0.83 | KMT2A (0.66) | KMT2AMEN1PKMGAAMAPT | |
| SCHEMBL11197746 | 0.81 | GAA (0.67) | KMT2AMEN1PKMGAAMAPT | |
| SCHEMBL5052133 | 0.81 | GAA (0.62) | KMT2AMEN1PKMGAAMAPT | |
| SCHEMBL9795841 | 0.80 | KMT2A (0.50) | KMT2AMEN1PKMGAAMAPT | |
| SCHEMBL7353123 | 0.79 | KMT2A (0.61) | KMT2AMEN1PKMGAAMAPT | |
| SCHEMBL11196756 | 0.79 | MAPT (0.68) | KMT2AMEN1PKMGAAMAPT | |
| SCHEMBL112411 | 0.79 | GAA (0.67) | KMT2AMEN1PKMGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117373-B1 | HAIR TONIC | WELLA AG (DE) | 2004-07-14 | — | — | EP | claimed |
| US-20040062736-A1 | Hair growth promoter | DAMM PETER (DE) | 2004-04-01 | — | — | US | claimed |
| US-20030031639-A1 | Hair growth promoter | Wella GmbH (DE) | 2003-02-13 | — | — | US | claimed |
| US-6488922-B1 | APPLYING 1-(N-(2'-NITRO-4'-TRIFLUOROMETHYLPHENYL)AMINO)-2,3-PROPYLENE TO SCALP | WELLA AKTIENGESELLSCHAFT (DE) | 2002-12-03 | — | — | US | claimed |
| EP-1117373-A1 | HAIR TONIC | Wella Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | claimed |
| WO-2000019969-A1 | HAIR TONIC | WELLA AKTIENGESELLSCHAFT (DE) | 2000-04-13 | — | — | WO | claimed |
| EP-1426034-B1 | Hair growth tonic | WELLA AG (DE) | 2006-05-24 | — | — | EP | disclosed |
| EP-1117373-B1 | HAIR TONIC | WELLA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-1426034-A1 | Hair growth tonic | Wella Aktiengesellschaft (DE) | 2004-06-09 | — | — | EP | disclosed |
| EP-1426034-A1 | Hair growth tonic | Wella Aktiengesellschaft (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-20040062736-A1 | Hair growth promoter | DAMM PETER (DE) | 2004-04-01 | — | — | US | disclosed |
| US-6667028-B2 | For promoting growth and/or reducing androgenic loss of hair | WELLA AKTIENGESELLSCHAFT (DE) | 2003-12-23 | — | — | US | disclosed |
| US-20030031639-A1 | Hair growth promoter | Wella GmbH (DE) | 2003-02-13 | — | — | US | disclosed |
| US-6488922-B1 | APPLYING 1-(N-(2'-NITRO-4'-TRIFLUOROMETHYLPHENYL)AMINO)-2,3-PROPYLENE TO SCALP | WELLA AKTIENGESELLSCHAFT (DE) | 2002-12-03 | — | — | US | disclosed |
| EP-1117373-A1 | HAIR TONIC | Wella Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000019969-A1 | HAIR TONIC | WELLA AKTIENGESELLSCHAFT (DE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040062736-A1 | Hair growth promoter | NR5A1, CYP21A2, CYP17A1 | KMT2A 1487/4885MEN1 1295/4885PKM 4165/4885 |
| US-20030031639-A1 | Hair growth promoter | NR5A1, CYP21A2, CYP17A1 | KMT2A 1487/4885MEN1 1295/4885PKM 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.